Affinity Asset Advisors’s Perspective Therapeutics CATX Stock Holding History

Affinity Asset Advisors’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.4M	Buy	4,214,582 +1,050,000	+33%	+$3.97M	0.65%	43
2026 Q1	$13.2M	Buy	3,164,582 +2,864,582	+955%	+$12.1M	0.68%	39
2025 Q4	$825K	Hold	300,000	–	–	0.05%	88
2025 Q3	$1.03M	Sell	300,000 -750,000	-71%	-$2.73M	0.09%	85
2025 Q2	$3.61M	Sell	1,050,000 -1,174,196	-53%	-$3.1M	0.49%	48
2025 Q1	$4.74M	Buy	2,224,196 +924,196	+71%	+$2.77M	0.45%	45
2024 Q4	$4.15M	Buy	1,300,000 +800,000	+160%	+$6.53M	0.56%	40
2024 Q3	$6.67M	Sell	500,000 -50,000	-9%	-$665K	0.91%	37
2024 Q2	$5.48M	Buy	550,000 +40,000	+8%	+$578K	0.63%	42
2024 Q1	$6.07M	Buy	+510,000	New	+$4.35M	0.75%	39

Other funds holding CATX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Affinity Asset Advisors's CATX Position: Q2 2026 in Review

Affinity Asset Advisors increased its Perspective Therapeutics (CATX) stake by 33% in Q2 2026, buying an estimated $3.97M and bringing the position to 4,214,582 shares worth $14.4M. The position accounts for 0.65% of the portfolio, ranked #43.

Affinity Asset Advisors first reported a position in CATX in Q1 2024 and has held it in 10 quarters since. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

Affinity Asset Advisors held 4,214,582 shares of Perspective Therapeutics worth $14.4M as of Q2 2026.
Affinity Asset Advisors bought 1,050,000 Perspective Therapeutics shares in Q2 2026, an estimated $3.97M.
Perspective Therapeutics made up 0.65% of Affinity Asset Advisors's portfolio in Q2 2026, its #43 holding.
Affinity Asset Advisors first reported a position in Perspective Therapeutics in Q1 2024 and has held it in 10 quarters since.
132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.